{
    "clinical_study": {
        "@rank": "164997", 
        "arm_group": {
            "arm_group_label": "Pigmanorm Cream, Q-switched Ruby laser,solar lentigines", 
            "arm_group_type": "Experimental", 
            "description": "Solar lentigines on the left back of the hand side are treated with Pigmanorm Cream once a day for 7 weeks. Solar lentigines on the right back of the hand side are treated with a Q-switched Ruby laser at Baseline and if required at day 28."
        }, 
        "brief_summary": {
            "textblock": "Benign pigmented lesions as solar lentigines are a common finding in Caucasian individuals.\n      Their removal may be requested for aesthetic reasons.\n\n      The goal of the study is comparing the efficacy and tolerance of two different therapy\n      modalities established for treating solar lentigines.\n\n      The right back of the hand side will be treated with the Q-switched SINON Rubin 694nm Laser,\n      the left back of the hand side with a hydrochinon containing bleaching cream (Pigmanorm\u00ae\n      cream).\n\n      The investigators estimate that a physical therapy with a Q-switched Rubin laser system is\n      more effective in the removal of solar lentigines than a topical chemical therapy with a\n      hydrochinon containing bleaching cream."
        }, 
        "brief_title": "Comparative Study of the Therapy of Solar Lentigines With a Q-switched Rubin Laser Versus a Bleaching Cream", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Solar Lentigines", 
        "condition_browse": {
            "mesh_term": "Lentigo"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 50\n\n          -  female patient must be in post-menopause (> 2 years)\n\n          -  Clinically and dermoscopic confirmed solar lentigines on both sides back of the hands\n\n        Exclusion Criteria:\n\n          -  non melanocytic pigmentation, vitiligo, melanoma and suspicion of melanoma\n\n          -  intolerance against an ingredience of pigmanorm\u00ae cream\n\n          -  acute inflammation or eczema on back of the hands\n\n          -  patients with renal disease\n\n          -  intake of photosensibilisating medication in the past 3 months\n\n          -  treatment of solar lentigines on back of the hands in the past 6 months\n\n          -  solarium or sun exposure about 6 weeks before and after treatment\n\n          -  immunsuppressed patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02153697", 
            "org_study_id": "KEK-ZH-Nr. 2013-0435"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pigmanorm Cream, Q-switched Ruby laser,solar lentigines", 
                "description": "Solar lentigines on the right back of the hand side are treated with the Q-switched SINON Ruby Laser at Baseline and if required at day 28.", 
                "intervention_name": "Q-switched SINON Ruby Laser", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Pigmanorm Cream, Q-switched Ruby laser,solar lentigines", 
                "description": "Solar lentigines on the left back of the hand side are treated once a day during 7 weeks with Pigmanorm cream, a bleaching cream containing hydrochinon.", 
                "intervention_name": "Pigmanorm Cream", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "solar lentigines", 
            "Q-switches Laser", 
            "bleaching cream"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "contact": {
                "email": "laurence.imhof@usz.ch", 
                "last_name": "Laurence Imhof, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland"
                }, 
                "name": "University Hospital Zurich, Division of Dermatology"
            }, 
            "investigator": {
                "last_name": "Laurence Imhof, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "1", 
        "official_title": "Comparative Study Investigating the Therapy of of Solar Lentigines With the Q-switched SINON Rubin 694nm Laser Versus Pigmanorm\u00ae Cream", 
        "overall_contact": {
            "email": "laurence.imhof@usz.ch", 
            "last_name": "Laurence Imhof, MD"
        }, 
        "overall_contact_backup": {
            "email": "reinhard.dummer@usz.ch", 
            "last_name": "Reinhard Dummer, Professor, MD"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Ethikkommission", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy objective is to evaluate the clearing of pigmentation(percentage of clearing) following a quartile scale of poor (25% clearance), fair (26-50% clearance), good (51-75% clearance), and excellent (76-100% clearance).", 
            "measure": "Evaluation of clearing of pigmentation", 
            "safety_issue": "No", 
            "time_frame": "140 days (Baseline, Day 28, Day 56, Day 140)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02153697"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Adverse effects are noted at each visit.", 
                "measure": "Evaluation of safety profile", 
                "safety_issue": "Yes", 
                "time_frame": "140 days (Baseline, Day 28, Day 56, Day 140)"
            }, 
            {
                "description": "The clearing of pigmentation (percentage of clearing) following a quartile scale of poor (25% clearance), fair (26-50% clearance), good (51-75% clearance), and excellent (76-100% clearance) is assessed at day 140 from Baseline ( = 3 months after finishing treatment).", 
                "measure": "Change from Baseline in Pigmentation at day 140", 
                "safety_issue": "No", 
                "time_frame": "Long term outcome is assessed 3 months after finishing treatment."
            }
        ], 
        "source": "University of Zurich", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Zurich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}